30-day average of 15 articles · scale −100 to +100
Across 15 scored articles from Oct 17 to Nov 15, 2026 (UTC),
the average sentiment of Amgen news is Somewhat Bullish (+44)
on a scale from −100 to +100.
That is up 10 points from the previous 30 days (+34).
📊 Amgen reported $38.9B revenue and $9.4B net income for fiscal 2026.
🏦 Company maintained 6.3x debt-to-equity ratio with $8.1B free cash flow.
Slightly Bullish +25
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
AI-generated analysis
Key insights
📊 Amgen reported revenue of approximately $38.9 billion and net income of nearly $9.4 billion for the 12 months ended Sept. 30, 2026.
🏦 The company maintained a debt-to-equity ratio of roughly 6.3x and generated free cash flow of about $8.1 billion as of Dec. 31, 2025.
📈 Amgen is projected to achieve roughly 3% revenue growth in fiscal 2026, reaching around $37.8 billion despite being a mature business.
🤝 Amgen reached a deal with the U.S. government to lower prices on key drugs Aimovig and Amjevita in exchange for tariff exemptions for three years.
🏭 Nearly 77% of Amgen's revenues in 2025 came from sales to three large distributors: McKesson, Cencora, and Cardinal Health.
💊 The company possesses six drug franchises that generate $1 billion-plus in annual revenue, providing a stable cash flow base.
📉 Amgen is characterized as an affordable option for value-conscious investors based on its significantly lower Forward P/E and P/S ratios.
📈 Bullish signals
💊Amgen maintains a diversified portfolio across oncology and rare diseases, providing a steady business model with six drug franchises generating over $1 billion in annual revenue each.
📈The company is projected to achieve roughly 3% revenue growth in fiscal 2026, reaching around $37.8 billion, supported by its massive scale and cash generation capabilities.
🤝Amgen secured a strategic deal with the U.S. government to lower prices on key drugs Aimovig and Amjevita in exchange for exemption from pharmaceutical tariffs for three years.
📉 Risk factors
📉The company faces substantial competition from biosimilars and generics, which can erode the market share of its older products.
📉Operational risks include a heavy reliance on specific manufacturing facilities in Puerto Rico and California.
Article
The article compares Amgen (AMGN) and Vertex Pharmaceuticals (VRTX), highlighting Amgen's diversified business model across oncology and rare diseases versus Vertex's high-growth specialization in genetic conditions. It notes that Amgen sells primarily through three large distributors, which accounted for nearly 77% of its revenues in 2025, adding a layer of customer concentration risk to the business.
Financial data reveals that in the 12 months ended Sept. 30, 2026, Amgen generated revenue of approximately $38.9 billion and net income of nearly $9.4 billion. The company maintains a debt-to-equity ratio of roughly 6.3x and produced free cash flow of about $8.1 billion for the fiscal year ended Dec. 31, 2025.
Amgen faces competition from biosimilars and pricing pressure but is positioned to achieve roughly 3% revenue growth in 2026, reaching around $37.8 billion. The company recently reached a deal with the U.S. government to lower prices on key drugs like Aimovig and Amjevita in exchange for exemption from pharmaceutical tariffs for three years.
Analysts view Amgen as an affordable option for value-conscious investors due to its lower Forward P/E and P/S ratios compared to Vertex. While not a fast-growing company by sales, its scale allows it to pursue future growth through acquisitions, supported by six drug franchises generating over $1 billion in annual revenue each.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Drug pricingRegulatory approvalAI-generated analysis
The article compares Amgen (AMGN) and Vertex Pharmaceuticals (VRTX), highlighting Amgen's diversified business model across oncology and rare diseases versus Vertex's high-growth specialization in genetic conditions. It notes that Amgen sells primarily through three large distributors, which accounted for nearly 77% of its revenues in 2025, adding a layer of customer concentration risk to the business.
Financial data reveals that in the 12 months ended Sept. 30, 2026, Amgen generated revenue of approximately $38.9 billion and net income of nearly $9.4 billion. The company maintains a debt-to-equity ratio of roughly 6.3x and produced free cash flow of about $8.1 billion for the fiscal year ended Dec. 31, 2025.
Amgen faces competition from biosimilars and pricing pressure but is positioned to achieve roughly 3% revenue growth in 2026, reaching around $37.8 billion. The company recently reached a deal with the U.S. government to lower prices on key drugs like Aimovig and Amjevita in exchange for exemption from pharmaceutical tariffs for three years.
Analysts view Amgen as an affordable option for value-conscious investors due to its lower Forward P/E and P/S ratios compared to Vertex. While not a fast-growing company by sales, its scale allows it to pursue future growth through acquisitions, supported by six drug franchises generating over $1 billion in annual revenue each.
📊 Amgen reported $38.9B revenue and $9.4B net income for fiscal 2026.
🏦 Company maintained 6.3x debt-to-equity ratio with $8.1B free cash flow.
📈 Projected 3% revenue growth to $37.8B in fiscal 2026 despite maturity.
🤝 Reached U.S. deal lowering Aimovig/Amjevita prices for tariff exemptions.
💊 Six franchises generate over $1B annually, ensuring stable cash flow.
📊 Amgen reported revenue of approximately $38.9 billion and net income of nearly $9.4 billion for the 12 months ended Sept. 30, 2026.
🏦 The company maintained a debt-to-equity ratio of roughly 6.3x and generated free cash flow of about $8.1 billion as of Dec. 31, 2025.
📈 Amgen is projected to achieve roughly 3% revenue growth in fiscal 2026, reaching around $37.8 billion despite being a mature business.
🤝 Amgen reached a deal with the U.S. government to lower prices on key drugs Aimovig and Amjevita in exchange for tariff exemptions for three years.
🏭 Nearly 77% of Amgen's revenues in 2025 came from sales to three large distributors: McKesson, Cencora, and Cardinal Health.
💊 The company possesses six drug franchises that generate $1 billion-plus in annual revenue, providing a stable cash flow base.
📉 Amgen is characterized as an affordable option for value-conscious investors based on its significantly lower Forward P/E and P/S ratios.
Bullish Signals
Six franchises generate over $1B annual revenue each.
Projected 3% revenue growth to $37.8B in fiscal 2026.
Secured U.S. government deal for tariff exemption.
Risk Factors
Biosimilars threaten older product market share.
Reliance on Puerto Rico/California facilities creates risk.
Bullish Signals
Amgen maintains a diversified portfolio across oncology and rare diseases, providing a steady business model with six drug franchises generating over $1 billion in annual revenue each.
The company is projected to achieve roughly 3% revenue growth in fiscal 2026, reaching around $37.8 billion, supported by its massive scale and cash generation capabilities.
Amgen secured a strategic deal with the U.S. government to lower prices on key drugs Aimovig and Amjevita in exchange for exemption from pharmaceutical tariffs for three years.
Risk Factors
The company faces substantial competition from biosimilars and generics, which can erode the market share of its older products.
Operational risks include a heavy reliance on specific manufacturing facilities in Puerto Rico and California.
Amgen (AMGN) is analyzed as a high-performing biotechnology peer that currently trades at a valuation discount compared to its largest competitor, Johnson & Johnson. Despite ranking second among six major drugmakers in both revenue growth and operating margins over the last four fiscal quarters, investors pay significantly lower multiples for Amgen's earnings. The article highlights that this pricing discrepancy does not reflect weaker performance, as Amgen has delivered superior profitability per sales dollar while maintaining robust top-line expansion.
Amgen's financial strength is driven by a portfolio of six key medicines that collectively account for over 70% of product sales and grew 27% year-over-year in the third quarter of 2026. This growth effectively offsets declines in older blockbuster drugs like ENBREL, which saw sales fall 32.9%. Specific high-growth assets include Repatha, which generated $1.1 billion in quarterly revenue with a 37% increase, and EVENITY, which rose 39% to $751 million.
Management has raised its full-year 2026 revenue guidance to a range of $38.9 billion to $39.7 billion, exceeding previous projections and indicating continued sales momentum. Operating margins have improved consistently over the past two years, climbing from 19.1% in late 2024 to 32.4% in the most recent period. While year-end spending is expected to rise, the company maintains a strong outlook for sustaining these margin levels into 2027.
Despite its superior growth and margin profile relative to peers like Johnson & Johnson and AbbVie, Amgen's P/E ratio remains lower than that of J&J or AbbVie. The article suggests that the current market price does not fully reward the company's lead in profitability and revenue expansion. Investors are advised to watch the full-year 2026 results expected in February 2027 to confirm if management can meet its raised sales targets.
📊 AMGN ranks second among six major drugmakers in revenue growth and operating margins.
💰 Investors pay 27x earnings for AMGN versus 42x for Johnson & Johnson.
🚀 Six core medicines drove a 27% year-over-year growth in product sales.
💊 Repatha generated $1.1 billion quarterly revenue with a 37% increase.
📈 Operating margins expanded from 19.1% to 32.4% over the latest twelve months.
📊 Amgen ranks second among six major drugmakers in both revenue growth and operating margins over the latest four fiscal quarters.
💰 Investors pay 27.0 times earnings for Amgen compared to 42.0 times for Johnson & Johnson, despite Amgen's superior profitability metrics.
🚀 Six core medicines drove a 27% year-over-year growth in product sales during the third quarter of 2026.
💊 Repatha generated $1.1 billion in quarterly revenue with a 37% increase, while EVENITY sales rose 39% to $751 million.
📉 Older drug ENBREL sales declined 32.9% in 2025, but high-growth assets more than compensated for the loss.
📈 Operating margins expanded from 19.1% in late 2024 to 32.4% in the most recent twelve-month period.
🔮 Management raised its 2026 revenue forecast to a range of $38.9 billion to $39.7 billion, exceeding prior guidance.
⚠️ The article notes that Amgen's lower P/E ratio does not reflect its lead over peers in growth and margin performance.
📅 Full-year 2026 results are expected to be reported in February 2027 against the raised revenue range.
Bullish Signals
Ranked #2 among major drugmakers in revenue growth and operating margins.
Risk Factors
P/E lower than peers despite superior growth and margins.
ENBREL sales fell 32.9% in 2025 to $2.23 billion.
Operating expenses expected to rise meaningfully in Q4 2026.
Bullish Signals
Amgen ranked second among six major drugmakers in both revenue growth and operating margins over the latest four fiscal quarters.
The company achieved a 32.4% operating margin, significantly higher than Johnson & Johnson's 25.7%, demonstrating superior profitability per sales dollar.
Six key medicines collectively grew 27% year-over-year in Q3 2026, outpacing the 8% growth in total product sales.
Repatha recorded $1.1 billion in quarterly sales with a 37% increase, while EVENITY rose 39% to $751 million.
Management raised its full-year 2026 revenue forecast to $38.9-$39.7 billion, exceeding the previous August projection of $38.8 billion.
Operating margins have risen for two consecutive years, climbing from 19.1% in late 2024 to 32.4% in the most recent period.
Risk Factors
Amgen trades at a lower P/E multiple than peers like Johnson & Johnson and AbbVie despite having superior growth and margin performance.
Sales of older blockbuster drug ENBREL fell 32.9% in 2025 to $2.23 billion, creating reliance on newer high-growth assets.
Operating expenses are expected to rise meaningfully in the fourth quarter of 2026 following the company's usual year-end spending pattern.
Drug approvalNew drug indicationAI-generated analysis
Amgen presented new clinical data at the American Heart Association Scientific Sessions 2026 supporting earlier use of its blockbuster drug Repatha for high-risk cardiovascular patients. The findings demonstrate that the therapy is highly cost-effective and beneficial for individuals without prior heart attacks or strokes, as well as those with chronic kidney disease.
These results align with regulatory approvals received in August 2025 from both the U.S. FDA and the European Commission, which have significantly widened Repatha's indications. This expansion effectively increases the eligible patient pool and reinforces the strategy of intensive LDL-C lowering across a broader risk spectrum within Amgen's cardiovascular portfolio.
Amgen shares are currently trading at $465.23, reflecting a 42.0% year-to-date gain as the market values the business based on the growing addressable market for Repatha. The primary focus now is on the speed of physician adoption for these expanded indications, as real-world uptake will determine how much this regulatory and clinical backing translates into tangible revenue concentration.
📈 New AHA 2026 data supports earlier Repatha use for high-risk patients.
💊 Findings confirm cost-effectiveness for CKD and prior heart attack/stroke patients.
✅ Results align with August 2025 FDA and European Commission approvals.
📊 Shares up 42% YTD reflecting confidence in growing Repatha market.
⏳ Adoption speed of new indications will impact cardiovascular revenue concentration.
📈 Amgen presented new data at the American Heart Association Scientific Sessions 2026 supporting earlier Repatha use for high-risk cardiovascular patients.
💊 The findings show Repatha is highly cost-effective and beneficial for patients without prior heart attacks or strokes, as well as those with chronic kidney disease.
✅ These results align with U.S. FDA and European Commission approvals from August 2025 that expanded Repatha's eligible patient pool.
📊 Amgen shares trade at $465.23, up 42.0% year to date, reflecting market confidence in the growing addressable market for Repatha.
⏳ The key challenge is determining how quickly physicians will adopt earlier Repatha use across these expanded indications.
💰 Real-world uptake of these new indications will directly influence revenue concentration within Amgen's cardiovascular portfolio.
Bullish Signals
Repatha data shows high cost-effectiveness for high-risk patients.
FDA/EC approvals expanded Repatha patient pool in Aug 2025.
Shares up 42.0% YTD as Repatha market grows.
Bullish Signals
Amgen presented new data at the American Heart Association Scientific Sessions 2026 showing Repatha is highly cost-effective and beneficial when used earlier for high-risk cardiovascular patients.
The findings align with U.S. FDA and European Commission approvals from August 2025 that expanded Repatha's eligible patient pool to include those without prior heart attacks or strokes.
Amgen shares are trading at $465.23, up 42.0% year to date, reflecting strong market valuation of the business as Repatha's addressable market grows.
Amgen Inc. (NASDAQ: AMGN) shares rose approximately 5.8% to $236.35 on Tuesday morning, driven by a strategic announcement following its fourth-quarter earnings report released after markets closed Monday. While the company reported profits that exceeded analyst expectations, it missed revenue targets, leading to a mixed market reaction that was ultimately overshadowed by its capital allocation plans.
During an online business review session held Tuesday morning, Amgen outlined a significant share repurchase program, committing to buy back between $6 billion and $7 billion of shares for the current year. This initiative builds upon a previously scheduled $6 billion buyback for the quarter, signaling strong management confidence in the company's financial position and commitment to returning value to shareholders despite the recent revenue miss.
Looking ahead, Amgen provided updated long-term guidance extending through 2030, projecting a compound annual growth rate (CAGR) in the mid-single digits for overall business. The company also forecast an adjusted operating margin of approximately 50% and expects adjusted earnings per share to grow at a high-single- to low-double-digit CAGR, offering investors a clear view of its future profitability trajectory.
📈 Amgen shares rose 5.8% after beating Q4 profit expectations.
💰 Company launches $6B-$7B new annual share repurchase program.
🚀 Long-term guidance projects mid-single-digit CAGR growth through 2030.
💵 EPS expected to grow high-single- to low-double-digit CAGR.
📈 Amgen shares gained 5.8% to $236.35 on Tuesday morning following the company's earnings release and subsequent business review.
💰 The company announced a new share repurchase program of $6 billion to $7 billion for the current year, adding to a previously scheduled $6 billion buyback.
📊 Amgen reported fourth-quarter profits that beat expectations, though revenue figures missed analyst forecasts.
🚀 Long-term guidance through 2030 projects mid-single-digit CAGR growth and an adjusted operating margin of approximately 50%.
💵 Management expects adjusted earnings per share to grow at a high-single- to low-double-digit CAGR over the next decade.
Bullish Signals
Shares rose 5.8% to $236.35.
Announced $6B-$7B share repurchase program.
Risk Factors
Missed Q4 revenue expectations, weighing on stock.
Bullish Signals
Amgen shares rose 5.8% to $236.35, reflecting investor confidence in the company's financial resilience despite missing revenue expectations.
The company announced a substantial new share repurchase program of $6 billion to $7 billion for the current year, demonstrating a strong commitment to returning capital to shareholders.
Risk Factors
Amgen missed fourth-quarter revenue expectations, which initially weighed on the stock despite beating profit estimates.
Drug approvalEarnings reportGuidance raisedAI-generated analysis
Amgen Inc (AMGN) reported strong third-quarter results with revenue rising 8% year-over-year to $10.4 billion, driven by a diverse portfolio where six key growth drivers accounted for over 70% of sales. The company highlighted robust cash generation, posting free cash flow of $3.7 billion in the quarter, and increased R&D spending by 11% alongside $600 million in capital expenditures to fuel innovation. Management maintained an optimistic tone, citing positive late-stage trial results and broad momentum across its therapeutic areas as key strengths.
Amgen significantly raised its full-year 2026 outlook, projecting revenue between $38.9 billion and $39.7 billion and non-GAAP EPS in the range of $22.90 to $23.70. This guidance lift was supported by double-digit growth across multiple blockbuster products, including Repatha, EVENITY, and TEZSPIRE, which collectively demonstrated strong prescription volume increases and market share gains. The company also saw substantial growth in its rare disease portfolio, with UPLIZNA sales surging 191% to $451 million.
The earnings call featured major positive updates on the clinical pipeline, including Phase III success for IMDELLTRA in small cell lung cancer and dazodalibep in Sjogren's disease. While management noted headwinds from a 6% decline in TEPEZZA sales due to prior-year inventory effects and anticipated higher fourth-quarter expenses, these were outweighed by the raised financial targets and successful commercial execution. The company emphasized its strategic focus on cardiovascular, oncology, immunology, and rare diseases while advancing biosimilar opportunities.
📈 Amgen Q3 revenue hit $10.4B, up 8% year-over-year.
💰 Free cash flow reached $3.7B for R&D flexibility.
🚀 Raised 2026 guidance to $38.9-$39.7B revenue.
💊 Repatha sales climbed 37% to $1.1 billion.
⚠️ Anticipates $2B expense pressure in 2026 despite growth.
📈 Amgen reported Q3 revenue of $10.4 billion, an 8% increase year-over-year, with six key growth drivers representing over 70% of total product sales.
💰 Free cash flow reached $3.7 billion in the third quarter, providing substantial financial flexibility for R&D and capital investments.
🚀 Management raised the 2026 revenue guidance to $38.9-$39.7 billion and non-GAAP EPS to $22.90-$23.70, reflecting strong commercial momentum.
💊 Repatha sales climbed 37% to $1.1 billion, driven by a 60% increase in U.S. new-to-brand prescriptions and expanded patient access.
🦴 EVENITY revenue rose 39% to $751 million, supported by broader physician adoption and strong volume share retention in Japan.
🌬️ TEZSPIRE sales increased 43% to $538 million, fueled by growth in severe uncontrolled asthma and positive Phase III results in eosinophilic esophagitis.
🧬 UPLIZNA sales surged 191% to $451 million across all approved indications, with significant patient growth in generalized myasthenia gravis.
🔬 IMDELLTRA sales more than doubled to $406 million following positive Phase III data showing a 40% reduction in death risk versus chemotherapy.
🩸 Dazodalibep demonstrated significant improvement in systemic Sjogren's disease activity in Phase III, with benefits sustained through week 48.
💉 Amgen completed enrollment in Phase III studies for MariTide in sleep apnea and cardiovascular outcomes, advancing toward potential launches.
📉 TEPEZZA sales declined 6% to $526 million primarily due to a prior-year inventory build, though the company expects sequential growth in Q4.
⚠️ The company anticipates higher fourth-quarter expenses and $2 billion-$2.1 billion of other income/expense pressure in 2026 despite raised revenue targets.
Bullish Signals
Q3 revenue hit $10.4B, up 8% YoY.
Free cash flow reached $3.7B in Q3.
Raised 2026 guidance to $38.9-$39.7B.
Repatha sales climbed 37% to $1.1B.
EVENITY revenue rose 39% to $751M.
Risk Factors
TEPEZZA sales declined 6% due to prior-year inventory build.
Q4 expenses rise; $2B-$2.1B pressure expected in 2026.
Sjogren's results not directly applicable to symptomatic study.
MariTide reimbursement difficult outside U.S. due to consumer-driven decisions.
Bullish Signals
Amgen reported Q3 revenue of $10.4 billion, an 8% year-over-year increase, with six key growth drivers accounting for over 70% of product sales.
Free cash flow reached $3.7 billion in the third quarter, demonstrating strong financial flexibility and operational efficiency.
Management raised the 2026 revenue guidance to $38.9-$39.7 billion and non-GAAP EPS to $22.90-$23.70, signaling confidence in future performance.
Repatha sales climbed 37% to $1.1 billion, driven by a 60% increase in U.S. new-to-brand prescriptions and expanded global patient treatment.
EVENITY revenue rose 39% to $751 million, supported by deepening physician adoption and strong market share retention in Japan.
TEZSPIRE sales increased 43% to $538 million, with Phase III results showing better remission outcomes in eosinophilic esophagitis.
UPLIZNA sales surged 191% to $451 million, supported by demand across all approved indications and expansion into 25 markets outside the U.S.
The innovative oncology portfolio grew 21% to $2.1 billion in sales, led by BLINCYTO growth of 27% to $496 million.
IMDELLTRA sales more than doubled to $406 million following positive Phase III data showing a 40% reduction in death risk versus chemotherapy.
The rare disease portfolio generated $1.6 billion in Q3 sales, up 21% year-over-year, reflecting successful international expansion and new approved uses.
Risk Factors
TEPEZZA sales declined 6% to $526 million in the third quarter, primarily due to a significant inventory build in the prior year complicating comparisons.
The company expects meaningful sequential increases in fourth-quarter operating expenses and anticipates $2 billion-$2.1 billion of other income/expense pressure in 2026.
Management cautioned that positive systemic Sjogren's results cannot be directly applied to the separate symptomatic Sjogren's study, requiring additional data for broader judgment.
Adoption of T-cell engagers like IMDELLTRA may face challenges outside specialist centers due to less experience managing cytokine release syndrome in community and urology sites.
Reimbursement for MariTide is expected to be more difficult outside the U.S., where treatment decisions are often consumer-driven rather than based on hard-endpoint outcomes.
Drug pricingEarnings reportGuidance raisedAI-generated analysis
Amgen reported third-quarter 2026 results on Tuesday, November 3, after the U.S. market close, raising its full-year 2026 outlook following a strong performance in newer therapies. The company's revenue increased 8% year over year to $10.4 billion, driven by significant growth in its obesity and cardiovascular portfolios while facing headwinds from biosimilar competition on established franchises.
Financial metrics for the quarter showed GAAP earnings per share rising to $7.08 from $5.93 a year earlier, with adjusted earnings per share increasing to $6.45. Adjusted operating income reached $4.7 billion, representing an operating margin of 47.3%. However, free cash flow declined to $3.7 billion from $4.2 billion in the prior-year quarter, primarily due to working-capital movements and favorable timing effects.
Amgen's product portfolio displayed a sharp divergence between emerging growth medicines and mature brands under pressure. High-growth drugs like Repatha, EVENITY, UPLIZNA, and IMDELLTRA delivered substantial revenue increases, whereas Prolia and XGEVA sales fell sharply due to global biosimilar launches. Additionally, Enbrel's net selling price decreased 14% reflecting ongoing impacts from the Inflation Reduction Act.
For fiscal year 2026, Amgen raised its revenue guidance to a range of $38.9 billion to $39.7 billion and adjusted earnings per share projections to $22.90 to $23.70. The company expects capital expenditure of approximately $2.6 billion and plans share repurchases of no more than $3.0 billion. CEO Robert Bradway highlighted the commercial portfolio, clinical advances, and late-stage pipeline as key drivers for durable growth.
Central to Amgen's future strategy is MariTide, an obesity candidate currently being tested in multiple Phase 3 studies targeting Type 2 diabetes, cardiovascular disease, heart failure, and sleep apnea. Management expressed confidence that the combination of its commercial portfolio strength and late-stage pipeline progress supports a positive long-term outlook for the biotechnology giant.
📈 Amgen raised full-year 2026 revenue guidance to $38.9B–$39.7B and adjusted EPS to $22.90–$23.70.
💰 Q3 revenue grew 8% YoY to $10.4B driven by new therapies like UPLIZNA (+191%).
⚠️ Established franchises Prolia and XGEVA declined 45% and 47% due to biosimilar competition.
📉 Enbrel net selling price fell 14% from Medicare Part D pricing under the Inflation Reduction Act.
🔬 MariTide advances in Phase 3 studies for obesity and Type 2 diabetes as key pipeline catalyst.
📈 Amgen raised its full-year 2026 revenue guidance to $38.9 billion–$39.7 billion and adjusted EPS guidance to $22.90–$23.70 following a strong Q3 performance.
💰 Third-quarter revenue grew 8% year-over-year to $10.4 billion, with product sales also up 8% driven by new therapies.
📊 GAAP earnings per share rose 19% to $7.08, while adjusted EPS increased 14% to $6.45 in the third quarter of 2026.
🚀 High-growth products Repatha, EVENITY, UPLIZNA, and IMDELLTRA delivered strong sales increases, with UPLIZNA revenue jumping 191%.
⚠️ Established franchises Prolia and XGEVA faced sharp declines of 45% and 47% respectively due to global biosimilar competition.
📉 Enbrel's net selling price fell 14% reflecting the ongoing impact of U.S. Medicare Part D price setting under the Inflation Reduction Act.
💸 Free cash flow declined to $3.7 billion from $4.2 billion, attributed mainly to working-capital movements and favorable prior-year timing effects.
🔬 R&D spending increased 11% to $2.1 billion as the company continues heavy investment in its pipeline despite lower acquisition-related costs.
💉 MariTide remains a central pipeline catalyst, now being tested in multiple Phase 3 studies for obesity and related conditions including Type 2 diabetes.
📈 Amgen expects capital expenditure of approximately $2.6 billion and share repurchases of no more than $3.0 billion for the year.
Bullish Signals
Raised FY2026 revenue guidance to $38.9B–$39.7B following strong Q3 performance.
Risk Factors
Prolia/XGEVA dropped 45%/47% due to biosimilar competition.
Enbrel price fell 14% under Inflation Reduction Act.
Free cash flow declined to $3.7B from $4.2B.
Bullish Signals
Amgen raised its full-year 2026 revenue guidance to $38.9 billion–$39.7 billion and adjusted EPS guidance to $22.90–$23.70 following a strong Q3 performance.
Third-quarter revenue grew 8% year-over-year to $10.4 billion, with product sales also up 8% driven by new therapies.
GAAP earnings per share rose 19% to $7.08, while adjusted EPS increased 14% to $6.45 in the third quarter of 2026.
High-growth products Repatha, EVENITY, UPLIZNA, and IMDELLTRA delivered strong sales increases, with UPLIZNA revenue jumping 191%.
MariTide remains a central pipeline catalyst, now being tested in multiple Phase 3 studies for obesity and related conditions including Type 2 diabetes.
CEO Robert Bradway expressed confidence that the commercial portfolio, clinical advances, and late-stage pipeline support Amgen's confidence in durable growth.
Risk Factors
Established franchises Prolia and XGEVA faced sharp declines of 45% and 47% respectively due to global biosimilar competition.
Enbrel's net selling price fell 14% reflecting the ongoing impact of U.S. Medicare Part D price setting under the Inflation Reduction Act.
Free cash flow declined to $3.7 billion from $4.2 billion, attributed mainly to working-capital movements and favorable prior-year timing effects.
Amgen (AMGN) is preparing to report its third-quarter earnings on November 3, facing a potential profit squeeze driven by rising operating expenses and legacy drug erosion. The company posted a fifth consecutive EPS beat in the prior quarter with revenue of $10.05 billion, but analysts now expect Q3 non-GAAP EPS of $5.79, down from $6.29 in Q2, as management warns of a meaningful sequential increase in costs.
Outgoing CFO Peter Griffith highlighted a specific $100 million R&D charge related to a business-development deal and noted that the operating margin has already slipped 0.5 percentage points in Q2. The company's full-year non-GAAP guidance for margins stands at 45% to 46%, lower than the 48% achieved in Q2, signaling pressure on profitability as it invests heavily in its pipeline.
Revenue growth will rely heavily on blockbuster brands Repatha, EVENITY, and TEZSPIRE to offset significant declines in legacy products like Prolia, which fell 32%, and XGEVA, which dropped 34% due to biosimilar competition. Additionally, the company is burning cash on nine ongoing global Phase III MariTide trials with capital expenditures guided at approximately $2.6 billion for the year.
Investors are closely watching whether Amgen can maintain its raised full-year revenue guidance of $38.2 billion to $39.4 billion while managing high debt levels of $57.3 billion and a transition to new CFO Thomas Dittrich. The stock has gained nearly 42% year-to-date, but the market will determine if the company's investment strategy in late-stage programs can sustain its growth trajectory without further margin contraction.
📉 Q3 consensus EPS expected at $5.79, down from Q2's $6.29.
💰 CFO warns of $100 million upfront R&D charge and rising expenses.
📉 Legacy drugs Prolia and XGEVA face severe biosimilar erosion.
🔬 Nine global Phase III MariTide trials funded with $2.6 billion capex.
Amgen is entering a critical reporting week following the declaration of its fourth-quarter dividend. The company's board approved a quarterly dividend of $2.52 per share, which will be payable to shareholders of record on November 20, with the payment date set for December 11.
Investors are awaiting the release of Amgen's third-quarter 2026 financial results, scheduled for publication after U.S. markets close on Tuesday, November 3. The earnings report will provide a comprehensive update on revenue, profitability, and demand across the company's therapeutic portfolio.
Following the earnings release, management is set to host a conference call at 4:30 p.m. Eastern Time to discuss the results and offer guidance for the remainder of 2026. This event will be pivotal in shaping market expectations regarding the company's development pipeline and future financial trajectory.
📅 Amgen declares $2.52 Q4 dividend payable Dec 11.
📊 Q3 2026 results released after markets close Nov 3.
🎙️ Management hosts call at 4:30 p.m. ET for guidance.
💰 Report assesses revenue, profitability, and portfolio demand.
🔬 Call shapes 2026 expectations and pipeline updates.
📅 Amgen declared a fourth-quarter dividend of $2.52 per share, payable on December 11 to shareholders of record on November 20.
📊 The company will release its third-quarter 2026 financial results after U.S. markets close on Tuesday, November 3.
🎙️ Management will host a conference call at 4:30 p.m. Eastern Time to discuss Q3 performance and provide forward-looking guidance.
💰 The upcoming earnings report will offer investors a fresh assessment of revenue, profitability, and demand across Amgen's portfolio.
🔬 Analysts expect the conference call to shape expectations for the remainder of 2026 and updates on the company's development pipeline.
Bullish Signals
Declared $2.52/share quarterly dividend.
Upcoming earnings to update revenue/profitability.
Bullish Signals
Amgen has maintained a consistent dividend policy by declaring a $2.52 per share quarterly dividend, signaling confidence in its cash flow generation.
The upcoming earnings release will provide investors with a timely update on revenue and profitability metrics across the company's therapeutic portfolio.
Amgen is preparing to release its third-quarter financial results on November 3, following the U.S. market close. The company faces a significant margin test as it anticipates higher operating expenses, specifically including a USD 100 million upfront charge related to a business-development deal recorded in research and development.
Management has raised its full-year revenue outlook to between USD 38.2 billion and USD 39.4 billion, with non-GAAP earnings per share guidance adjusted to USD 22.30 to USD 23.50. However, the company expects its full-year non-GAAP operating margin to moderate from the second-quarter level of 48% to a range of 45% to 46% of product sales.
Commercial performance remains critical as growth brands attempt to offset declining revenue from legacy products. While newer therapies like Repatha, Evenity, Tezspire, and Imdelltra showed strong double-digit or triple-digit revenue increases, established drugs Prolia and XGEVA suffered significant revenue declines of 32% and 34% respectively due to biosimilar competition.
Amgen is also investing heavily in its pipeline, with ongoing Phase 3 MariTide trials and capital expenditure guided at approximately USD 2.6 billion. Investors will closely monitor the November 3 report for updates on MariTide enrollment, manufacturing expansion plans, and whether the company can successfully absorb increased spending while maintaining profitability.
📅 Amgen releases Q3 results after U.S. market close on Nov 3.
💰 Operating expenses rise due to USD 100 million business deal payment.
📉 Full-year non-GAAP margins forecast to drop from 48% to 45-46%.
💊 Pipeline advances with nine global Phase 3 MariTide trials for olpasiran.
📅 Amgen is scheduled to release third-quarter results on Tuesday, November 3, after the U.S. market close.
💰 The company expects higher operating expenses including a USD 100 million upfront payment tied to a business-development deal.
📉 Management forecasts full-year non-GAAP operating margins will decrease from 48% in Q2 to a range of 45% to 46%.
🚀 Growth brands Repatha, Evenity, Tezspire, and Imdelltra drove revenue increases of 37%, 38%, 42%, and 115% respectively in the second quarter.
📉 Legacy products Prolia and XGEVA faced significant headwinds with revenue declines of 32% and 34% due to biosimilar competition.
💊 Amgen is advancing its pipeline with nine global Phase 3 MariTide trials involving olpasiran and xaluritamig.
🏗️ Capital expenditure for the year is guided at approximately USD 2.6 billion to support manufacturing expansion and R&D.
📈 Analysts expect third-quarter normalized earnings per share of USD 5.7876 and revenue of USD 10.08 billion.
🔍 Investors will focus on management's update regarding MariTide enrollment and manufacturing capacity during the earnings call.
Bullish Signals
Repatha revenue rose 37% to USD 953 million.
Evenity sales increased 38% to USD 714 million.
Tezspire growth reached 42% at USD 486 million.
Imdelltra surged 115% while expanding into Europe and China.
Risk Factors
Operating margins to drop from 48% to 45-46% due to spending and biosimilars.
Legacy products Prolia and XGEVA revenue fell 32% and 34% vs biosimilars.
$100M upfront charge for business deal recorded in R&D expenses.
Q3 EPS expected at $5.79, down from Q2's $6.29.
Bullish Signals
Growth brands demonstrated strong momentum with Repatha revenue rising 37% to USD 953 million, Evenity increasing 38% to USD 714 million, Tezspire gaining 42% to USD 486 million, and Imdelltra climbing 115% as it expands into Europe and China.
Management raised its full-year revenue outlook to a range of USD 38.2 billion to USD 39.4 billion, indicating confidence in overall top-line growth despite margin compression.
The company successfully delivered non-GAAP earnings per share of USD 6.29 in the second quarter, beating the consensus estimate of USD 5.62 with revenue reaching USD 10.05 billion.
Risk Factors
Management expects full-year non-GAAP operating margins to decline from 48% in the second quarter to a range of 45% to 46% due to higher spending and biosimilar pressure.
Legacy products Prolia and XGEVA faced substantial revenue declines of 32% and 34% respectively, driven by intense competition from biosimilars.
The company faces a planned increase in operating expenses including a USD 100 million upfront charge for a business-development deal recorded in R&D.
Analysts expect third-quarter normalized earnings per share of USD 5.7876, which is below the second-quarter result of USD 6.29, highlighting a sequential earnings decline.
Amgen (AMGN) has confirmed the date for its third-quarter 2026 financial results, scheduled to be released on November 3 after the close of U.S. markets. The company's investor conference call is set to begin at 4:30 p.m. Eastern Time and will feature CEO Robert A. Bradway alongside other senior management members.
This announcement provides investors with a specific near-term catalyst to monitor ahead of the earnings report. The event marks the next scheduled test of Amgen's operating performance, allowing the market to assess the company's ability to balance its commercial momentum with ongoing investments in its development pipeline.
Amgen stock was trading at EUR 413.03 in Berlin on October 29, reflecting a 2.99% increase from the previous session's close. While the specific earnings figures are not yet available, the confirmed date adds clarity to the company's quarterly calendar following recent updates regarding its clinical pipeline and dividend timetable.
The upcoming results will be critical for determining the direction of Amgen's share price, as investors will focus on management commentary and the forward-looking outlook provided during the webcast. The live event will be available to the public and archived for at least 90 days.
📅 Q3 2026 earnings scheduled for November 3 after U.S. markets close.
🎤 CEO Robert A. Bradway to host investor call at 4:30 p.m. ET.
💰 Stock rose 2.99% in Berlin, trading at EUR 413.03 on Oct 29.
🔬 Results will test commercial momentum and pipeline investment balance.
📡 Webcast live-streamed to public with 90-day archive availability.
📅 Amgen has officially scheduled its Q3 2026 earnings report for November 3, following the close of U.S. markets.
🎤 CEO Robert A. Bradway and senior management will host an investor conference call starting at 4:30 p.m. Eastern Time.
💰 Amgen stock traded at EUR 413.03 in Berlin on October 29, up 2.99% from the previous session.
🔬 The upcoming results will serve as a key test of the company's commercial momentum and pipeline investment balance.
📡 The earnings webcast will be live-streamed to the public and archived for at least 90 days.
📈 This announcement follows recent updates regarding Amgen's clinical pipeline and dividend schedule.
Bullish Signals
Stock gained 2.99% to EUR 413.03 on October 29.
Confirmed Nov 3 earnings date, reducing investor uncertainty.
Bullish Signals
Amgen stock gained 2.99% to EUR 413.03 in Berlin trading on October 29, indicating positive market sentiment ahead of the earnings release.
The company has provided clear calendar certainty by confirming the November 3 earnings date, reducing uncertainty for investors planning around the quarterly results.
Amgen announced positive late-breaking clinical data for its Phase 3 OASIZ-301 trial evaluating dazodalibep in patients with Sjogren's disease. The study demonstrated a statistically significant reduction in disease activity compared to placebo, with the four-week dosing regimen showing a 1.8-point greater improvement at Week 48 versus the control group.
The company reported that the least-squares mean change in disease activity was minus 5.6 points for the active treatment versus minus 3.8 points for placebo. Additionally, the trial observed statistically significant improvements in patient-reported dryness symptoms and a baseline ESSDAI score of 10.2.
Amgen also declared a quarterly dividend of USD 2.52 per share for the fourth quarter of 2026, with a record date of November 20, 2026, and an expected payment date of December 11, 2026. The stock was trading at EUR 401.05 on October 28, 2026, reflecting investor attention to these dual developments.
The company plans to present the OASIZ-301 results as Abstract 22 at the American College of Rheumatology Convergence on November 11, 2026. This presentation will provide further context alongside data for other assets like UPLIZNA and KRYSTEXXA during the conference.
📈 Phase 3 trial showed 1.8-point disease activity gap vs placebo at Week 48.
💧 Dazodalibep delivered significant improvements in patient-reported dryness symptoms over placebo.
💰 Declared USD 2.52 per share dividend for Q4 2026, payable Dec 11.
🗓️ Will present late-breaking OASIZ-301 results at ACR Convergence on Nov 11.
📈 Amgen's Phase 3 OASIZ-301 trial showed a 1.8-point placebo gap in disease activity reduction at Week 48 for dazodalibep in Sjogren's disease.
📊 The four-week dosing regimen achieved a minus 5.6 point change in disease activity versus a minus 3.8 point change for the placebo group.
💧 Patients treated with dazodalibep experienced statistically significant improvements in patient-reported dryness symptoms compared to placebo.
💰 Amgen declared a USD 2.52 per share dividend for Q4 2026, payable on December 11, 2026, to shareholders of record on November 20.
🗓️ The company will present the OASIZ-301 late-breaking results as Abstract 22 at the American College of Rheumatology Convergence on November 11, 2026.
📉 Amgen stock traded at EUR 401.05 on October 28, 2026, capturing market attention to the new clinical data and dividend announcement.
Bullish Signals
OASIZ-301 trial showed 1.8-point superiority over placebo at Week 48.
Dazodalibep achieved -5.6 point change vs -3.8 for placebo in Sjogren's.
Study improved patient-reported dryness symptoms for Sjogren's population.
Declared USD 2.52 quarterly dividend for Q4 2026.
Bullish Signals
Amgen's Phase 3 OASIZ-301 trial demonstrated a statistically significant 1.8-point superiority over placebo in reducing disease activity at Week 48.
The dazodalibep treatment achieved a minus 5.6 point change in disease activity versus minus 3.8 points for placebo, indicating robust efficacy in Sjogren's disease.
The study reported statistically significant improvements in patient-reported dryness symptoms, addressing a key unmet need for the Sjogren's population.
Amgen declared a USD 2.52 per share quarterly dividend for Q4 2026, providing consistent cash returns to shareholders with a payment date of December 11.
Jefferies has raised its price target for Amgen to USD 428.00, increasing it from a previous level of USD 410.00 on October 26, 2026. This analyst upgrade follows the company's strong second-quarter performance, where Amgen reported revenue of USD 10.05 billion, representing a 9.50% increase compared to the same period in the prior year.
The financial results for the quarter were robust, with consolidated net income reaching USD 2.38 billion and diluted earnings per share hitting USD 4.37. Market data indicates that these actual figures significantly exceeded consensus estimates, with revenue surpassing expectations of USD 9.43 billion and adjusted earnings per share beating the USD 5.62 estimate.
Amgen's stock price on October 27, 2026, was trading at USD 447.00 on Nasdaq, which is notably higher than Jefferies' revised target of USD 428.00. The company maintains a market capitalization of USD 241.7 billion and a price-to-earnings ratio of 27.76, trading near its 52-week high of USD 450.98.
📈 Jefferies raised Amgen price target to USD 428 on October 26, 2026.
💰 Q2 2026 revenue hit USD 10.05 billion, up 9.5% year-over-year.
🚀 Revenue of USD 10.05 billion beat market consensus of USD 9.43 billion.
📉 Stock traded at USD 447 on October 27, above Jefferies' new target.
📅 Next earnings release scheduled for November 3, 2026.
📈 Jefferies raised its Amgen stock price target from USD 410.00 to USD 428.00 on October 26, 2026.
💰 Amgen reported second-quarter 2026 revenue of USD 10.05 billion, a 9.50% year-over-year increase.
📊 Diluted earnings per share reached USD 4.37, exceeding the analyst consensus estimate of USD 5.62 in adjusted comparison.
🚀 Revenue of USD 10.05 billion surpassed the market consensus expectation of USD 9.43 billion.
📉 Amgen stock traded at USD 447.00 on October 27, 2026, trading above Jefferies' new target price.
🏢 The company holds a market capitalization of USD 241.7 billion with a P/E ratio of 27.76.
📅 Investors await the next earnings release scheduled for November 3, 2026.
Bullish Signals
Jefferies raised price target to $428 after strong Q2 results.
Bullish Signals
Jefferies raised its price target for Amgen to USD 428.00 from USD 410.00 following strong Q2 results.
Second-quarter revenue reached USD 10.05 billion, up 9.50% year-over-year, exceeding consensus estimates of USD 9.43 billion.
Diluted earnings per share of USD 4.37 were reported for the period, beating adjusted analyst expectations.
Consolidated net income for the quarter totaled USD 2.38 billion.
Amgen announced positive Phase 3 trial data for its Imdelltra and Imfinzi combination therapy in extensive-stage small cell lung cancer on October 24, 2026. The DeLLphi-305 study demonstrated a 58 percent lower risk of death compared to Imfinzi alone, with median overall survival reaching 21.10 months versus 12.70 months for the monotherapy.
The clinical results showed that nearly 80 percent of patients in the combination group remained alive after one year, compared to 53 percent with Imfinzi alone. Progression-free survival was also significantly improved at 7.40 months versus 1.90 months. However, the combination therapy did carry a higher rate of Grade 3 or higher adverse events (20.90 percent) compared to the monotherapy (10.80 percent).
This data provides a fresh clinical reference point for Amgen's oncology pipeline, which generated approximately USD 2 billion in revenue during the second quarter. While Imdelltra sales have already risen 115 percent year over year to USD 288 million, the company faces the next tests of regulatory review and commercial execution to determine if this new indication can materially reshape its growth trajectory.
Amgen raised its full-year 2026 revenue outlook to between USD 38.2 billion and USD 39.4 billion following strong second-quarter earnings of USD 10.05 billion. The stock, trading around EUR 395.63 with a market cap of USD 237.5 billion, now has a concrete pipeline variable ahead of its next reported results.
📈 DeLLphi-305 trial showed 58% lower death risk for Imdelltra/Imfinzi combo in small cell lung cancer.
⏱️ Median overall survival reached 21.10 months with the combination versus 12.70 months with Imfinzi alone.
💰 Q2 oncology revenue hit USD 2 billion, driven by 115% YoY growth in Imdelltra sales to USD 288 million.
📈 Full-year 2026 revenue outlook raised to USD 38.2-39.4 billion following strong second-quarter performance.
🏢 Q2 adjusted EPS was USD 6.29 on total revenue of USD 10.05 billion.
📈 Amgen reported a 58 percent lower risk of death in the DeLLphi-305 Phase 3 trial for an Imdelltra and Imfinzi combination in extensive-stage small cell lung cancer.
⏱️ Median overall survival reached 21.10 months with the combination versus 12.70 months with Imfinzi alone, while progression-free survival improved to 7.40 months from 1.90 months.
👥 Nearly 80 percent of patients in the combination group were alive after one year compared to 53 percent for those receiving Imfinzi alone.
⚠️ The combination therapy resulted in a higher incidence of Grade 3 or higher treatment-related adverse events at 20.90 percent versus 10.80 percent for Imfinzi monotherapy.
💰 Amgen's second-quarter oncology portfolio generated approximately USD 2 billion, with Imdelltra sales rising 115 percent year over year to USD 288 million.
📈 The company raised its full-year 2026 revenue outlook to a range of USD 38.2 billion to USD 39.4 billion following the strong second-quarter performance.
🏢 Amgen reported second-quarter adjusted earnings per share of USD 6.29 on total revenue of USD 10.05 billion.
📉 The stock traded at EUR 395.63 with a market capitalization of USD 237.5 billion as of October 23, 2026.
Bullish Signals
DeLLphi-305 trial showed 58% lower death risk with combo therapy.
Risk Factors
Combo therapy adverse events rose to 20.90% vs 10.80% alone.
Regulatory approval needed before new indication drives growth.
Bullish Signals
Amgen demonstrated a 58 percent lower risk of death in the DeLLphi-305 Phase 3 trial for its Imdelltra and Imfinzi combination therapy.
Median overall survival in the trial reached 21.10 months with the combination versus 12.70 months with Imfinzi alone, indicating a significant efficacy boost.
Nearly 80 percent of patients in the combination group survived past one year compared to 53 percent for the monotherapy group.
Amgen raised its full-year 2026 revenue outlook to USD 38.2 billion-USD 39.4 billion following a strong second quarter.
The company achieved second-quarter revenue of USD 10.05 billion and adjusted earnings per share of USD 6.29.
Risk Factors
The Imdelltra and Imfinzi combination therapy was associated with a higher rate of Grade 3 or higher treatment-related adverse events at 20.90 percent compared to 10.80 percent for Imfinzi alone.
Regulatory review and commercial execution remain critical next steps required before the new indication can materially reshape the company's growth.
Amgen reported a 10% rise in second-quarter revenue and continued to beat earnings estimates, reinforcing its investment narrative of disciplined capital returns and expanding newer therapies. The company maintains a dividend yield of 2.5% with annual increases of 8% from 2020 to 2025, signaling a commitment to shareholder value alongside operational execution.
Analysts project Amgen's revenue to grow at 3.6% annually through 2029, supported by a diversified portfolio in cardiometabolic, oncology, and rare disease sectors. Profit margins are expected to expand from 23.0% today to 25.2% over the next three years, driven by cost control and a shift toward higher-margin therapies as older franchises face pricing pressure and biosimilar competition.
Valuation models suggest a consensus price target of US$390.94, which represents approximately 7.8% downside from the current share price of US$421.51. While some bullish analysts forecast revenue reaching US$48.0b by 2029, the consensus view relies on the successful conversion of late-stage assets like MariTide and olpasiran to offset exclusivity losses in key products such as Otezla.
The article highlights that Amgen's fair value indicates little room for error given the active risks of drug pricing and competitive erosion. Investors are advised to evaluate whether the company can sustain growth drivers like Repatha and TEZSPIRE while navigating the transition to newer oncology agents and biosimilars in its portfolio.
📈 Q2 revenue rose 10% while beating earnings estimates.
💰 Dividend yield is 2.5% with 8% annual growth.
🔬 Analysts forecast 3.6% annual revenue growth through 2029.
💹 Profit margins modeled to expand from 23.0% to 25.2%.
📈 Amgen reported a 10% increase in second-quarter revenue and beat earnings estimates, supporting its thesis of operational resilience.
💰 The company maintains a 2.5% dividend yield with an 8% annual growth rate from 2020 to 2025, reflecting disciplined capital returns.
🔬 Analysts forecast revenue growth of 3.6% per year through 2029, driven by cardiometabolic, oncology, and rare disease therapies.
💹 Profit margins are modeled to expand from 23.0% today to 25.2% in three years as the portfolio shifts toward higher-margin products.
📉 The consensus price target of US$390.94 implies a 7.8% downside from the current share price of US$421.51.
⚠️ Key risks include drug pricing pressure and competitive erosion, particularly around Otezla and bone health therapies.
🧬 Growth depends on the successful commercialization of late-stage assets like MariTide, olpasiran, and newer oncology agents.
🔄 Amgen must offset exclusivity losses in older drugs with expansion in biosimilars and newer therapeutic areas.
Bullish Signals
Revenue rose 10% in Q2, beating estimates.
Dividend yield is 2.5% with 8% annual increases.
Analysts project profit margins expanding to 25.2%.
Diversified portfolio supports earnings growth through 2029.
Risk Factors
Consensus price target is 7.8% below current share price.
Risks include drug pricing pressure and competitive erosion.
Forecast relies on asset conversion to offset exclusivity losses.
Bullish Signals
Amgen reported a 10% rise in second-quarter revenue and beat earnings estimates, demonstrating solid quarterly execution.
The company maintains a dividend yield of 2.5% with annual increases of 8% from 2020 to 2025, showcasing disciplined capital returns.
Analysts project profit margins to expand from 23.0% today to 25.2% in three years due to cost control and a richer tilt toward higher-margin therapies.
Amgen's diversified portfolio in cardiometabolic, oncology, and rare disease sectors is expected to support earnings growth through 2029.
Risk Factors
The consensus price target of US$390.94 sits about 7.8% below the current share price of US$421.51, indicating a potential downside.
Active risks include drug pricing pressure and competitive erosion, particularly around products like Otezla and bone health therapies.
The consensus forecast relies on the successful conversion of late-stage assets to offset exclusivity losses in key older drugs.
Amgen (AMGN) has demonstrated a distinct decoupling from the broader S&P 500 index over the past year, capturing roughly two-thirds of market gains while absorbing only about a quarter of losses. Despite this relative downside protection during average down days, the stock's volatility remains significantly higher than the index at 29.4% annually, indicating that its price swings are largely driven by company-specific factors rather than general market movements.
Financial performance highlights a transition period for the biopharmaceutical giant, with sales of legacy drugs Prolia and XGEVA falling 33% in fiscal Q2 2026 due to biosimilar competition. Conversely, the six key growth drivers grew by 26% during the same quarter, signaling a strategic shift where future revenue depends on the successful replacement of declining legacy products with newer therapies.
The company is heavily investing in scaling manufacturing for MariTide, aiming to launch it as a monthly or less frequent obesity therapy. While Amgen has historically compensated investors for its higher volatility with returns of 19.4% annually over five years versus 13.4% for the S&P 500, analysts note that this extra return roughly matches the added risk, suggesting the stock is fairly priced relative to its turbulence.
Looking ahead, the crucial metric for investors will be whether Amgen can successfully replace lost sales from legacy drugs with revenue from newer treatments like MariTide. The company's ability to execute this transition without adding excessive portfolio risk remains a key consideration for shareholders holding positions alongside broad market exposure.
📉 AMGN captured two-thirds of S&P 500 gains while absorbing only a quarter of losses through October 2026.
📊 Stock showed 29.4% annual volatility, significantly higher than the index's 12.7%.
💊 Legacy drug sales fell 33% in Q2 2026 due to biosimilar competition.
🚀 Six key growth drivers grew 26% in Q2 2026, offsetting legacy declines.
🏭 AMGN is scaling manufacturing for upcoming MariTide obesity therapy launch.
📉 Amgen captured about two-thirds of the S&P 500's gains while absorbing only about a quarter of its losses over the past year to October 15, 2026.
📊 The stock exhibited an annual volatility of 29.4% in the past year, significantly higher than the index's 12.7%, with price swings largely independent of broader market moves.
💊 Sales of legacy drugs Prolia and XGEVA fell 33% in fiscal Q2 2026 as rival biosimilar competitors entered the market.
🚀 The six key growth drivers for Amgen grew together by 26% in fiscal Q2 2026, offsetting declines in legacy product sales.
🏭 Amgen is scaling up manufacturing capabilities to support the upcoming launch of MariTide, a new monthly or less frequent obesity therapy.
📈 Over the past five years, Amgen returned 19.4% annually compared to 13.4% for the S&P 500, with volatility-adjusted returns nearly identical to the index.
Bullish Signals
Stock gained twice as much as the broader market last year.
Risk Factors
Legacy drug sales fell 33% in Q2 2026 due to biosimilars.
Annual volatility hit 29.4%, far exceeding S&P 500's 12.7%.
March 2026 loss was 9.4%, nearly double the S&P 500.
Bullish Signals
The stock captured about two-thirds of the broader market's gains while absorbing only about a quarter of its losses over the past year.
Sales of the six key growth drivers grew 26% in fiscal Q2 2026, demonstrating successful expansion in core therapeutic areas.
The company is actively scaling manufacturing for MariTide, positioning itself to launch a new monthly or less frequent obesity therapy.
Risk Factors
Sales of legacy drugs Prolia and XGEVA fell 33% from a year earlier in fiscal Q2 2026 due to the launch of biosimilar competitors.
The stock's annual volatility stood at 29.4% over the past year, significantly higher than the S&P 500's 12.7%, indicating substantial price swings independent of market trends.
During March 2026, Amgen lost about $935 on a $10,000 holding (a 9.4% fall), which was close to twice the decline of the S&P 500 during that month.
Company updateGuidance raisedAI-generated analysis
Amgen (AMGN) operates within a competitive landscape of six major pharmaceutical peers, ranking second in both sales growth and operating margins while trading at a premium valuation relative to some rivals. The company's financial profile shows it outperforming Johnson & Johnson in revenue growth and profitability, yet commanding a lower P/E multiple than AbbVie despite superior growth metrics. This valuation disconnect suggests the market prices in continued growth deceleration.
Amgen's performance is heavily driven by six key therapeutic areas that collectively accounted for nearly 70% of product sales in fiscal Q2 2026. While blockbuster drug Repatha saw a significant 37% sales increase, the company faces headwinds from biosimilar competition impacting Prolia and XGEVA, which combined sales fell by 33%. Overall revenue growth has slowed sequentially from previous years, with the market anticipating this trend to persist.
Management raised its full-year 2026 revenue guidance to a midpoint of $38.8 billion, representing approximately 5% growth over the prior year's reported results. However, executives warned that operating expenses will rise meaningfully in the third quarter due to increased spending on pipeline development and commercial brands, posing a potential risk to the company's historically strong operating margins.
The article concludes that investors should monitor Amgen's full-year 2026 revenue against its guidance range as the primary metric for assessing whether the stock's valuation assumptions regarding growth slowdown hold true. The narrative balances the success of core assets like Repatha against the erosion from biosimilars and rising cost pressures.
📊 Amgen ranks second among peers in sales growth and operating margin.
💰 Stock trades at 25.8x P/E, significantly lower than AbbVie's 78.8x multiple.
Amgen Inc. (NASDAQ:AMGN) closed at $414.87, posting an 18.6% return over the last six months compared to peers Biogen and Gilead. The article highlights that while Amgen reports a spectacular return on equity, this metric is significantly influenced by substantial borrowing rather than organic business profitability. In contrast, Gilead demonstrates superior asset efficiency with a 14.09% return on assets and the highest cash generation in the group, despite reporting a net loss due to acquisition-related charges.
Amgen's financial profile includes the largest dividend payout among the three companies, which is funded by its high level of debt. The stock trades at a forward multiple of 16.94x earnings, making it the most expensive of the group compared to Biogen's 13.65x and Gilead's 15.29x. Analysts note that Amgen faces the structural industry challenge of replacing revenue as patents expire, similar to its competitors.
Hedge fund data from Q2 2026 shows Amgen held by 66 funds with a combined stake value of approximately $3.14 billion, an increase in investment value from the previous quarter. The article concludes that while Amgen is a blue-chip payer dominating hedge fund portfolios, its valuation and debt structure present a different risk profile compared to the cash-rich but loss-reporting Gilead or the cheap but earnings-collapsed Biogen.
📈 AMGN delivered an 18.6% six-month return, outperforming peers relative to S&P 500.
💰 AMGN funds largest peer dividend via substantial borrowing rather than organic cash flow.
📉 AMGN's high ROE is driven by leverage instead of underlying business profitability.
🏦 AMGN trades at a forward multiple of 16.94x, the highest among peers.
📈 Amgen closed at $414.87 with an 18.6% six-month return, outperforming Gilead's 8.8% and Biogen's 30.5% relative to the S&P 500.
💰 Amgen pays the largest dividend of the three peers, but this payout is funded by substantial borrowing rather than organic cash flow generation.
📉 While Amgen shows a spectacular return on equity, the article attributes much of this performance to leverage rather than underlying business profitability.
🏦 Amgen trades at a forward multiple of 16.94x earnings, making it the most expensive valuation among Biogen, Gilead, and itself.
📊 Hedge fund holdings for Amgen increased in value to $3.14 billion in Q2 2026, held by 66 funds according to Insider Monkey data.
⚠️ All three companies face the permanent industry challenge of replacing revenue as patents expire, including Amgen's portfolio.
Bullish Signals
18.6% return over last six months.
Dominant blue-chip in hedge fund portfolios.
Risk Factors
Debt exceeds peers, inflating ROE and masking profitability.
Trades at 16.94x forward multiple vs Biogen/Gilead.
Dividend funded by borrowing creates leverage risk.
Bullish Signals
Amgen posted an 18.6% return over the last six months, outperforming Gilead and Biogen in absolute stock price gains during that period.
The company is a dominant blue-chip payer within hedge fund portfolios, indicating strong institutional confidence and liquidity.
Risk Factors
Amgen carries substantially more debt than its peers, which inflates its return on equity metric and masks underlying asset profitability.
The stock trades at the highest forward multiple (16.94x) among the three compared companies, suggesting a premium valuation relative to Biogen and Gilead.
Amgen relies on significant borrowing to fund its largest dividend payout, creating potential financial leverage risks if cash flows tighten.
Amgen Inc. received a Neutral rating with a USD 400 price target from Cantor Fitzgerald on October 5, 2026. The firm cited solid commercial execution but noted that expectations for Lp(a) products need to be reset following recent HORIZON results. Despite the neutral stance, the analyst acknowledged positive data emerging from Amgen's Sjogren's program as a key development.
Amgen reported strong second-quarter 2026 financial results with total revenue reaching USD 10.05 billion, representing a 10 percent year-over-year increase. GAAP diluted earnings per share were USD 4.37, while non-GAAP EPS stood at USD 6.29. The company generated USD 3.489 billion in free cash flow and maintained a robust non-GAAP operating margin of 48.4 percent on product sales.
Growth was primarily driven by established products, with Repatha revenue surging 37 percent to USD 953 million and EVENITY sales increasing 38 percent to USD 714 million. Additionally, Amgen announced positive Phase 3 results for dazodalibep in moderate-to-severe systemic Sjogren's disease on September 22, 2026, adding a significant clinical catalyst to its portfolio.
Amgen's market capitalization was valued at USD 218.5 billion as of October 6, 2026, with shares trading at USD 404.83 on Nasdaq. The stock is currently positioned in the upper half of its 52-week range, sitting below its analyst consensus target but reflecting confidence in its operating anchor and pipeline milestones.
📊 Cantor maintains Neutral rating with $400 price target for Amgen.
💰 Q2 revenue hit $10.05B, up 10% year-over-year.
📈 Repatha sales surged 37% to $953M driving growth.
🔬 Positive Phase 3 results announced for dazodalibep in Sjogren's.
💵 Free cash flow reached $3.489B in the second quarter.
📊 Cantor Fitzgerald reiterated a Neutral rating with a USD 400 price target for Amgen on October 5, 2026.
Amgen reported Q2 revenue of USD 10.05 billion, a 10 percent year-over-year increase driven by strong commercial execution.
Repatha sales surged 37 percent to USD 953 million, while EVENITY sales grew 38 percent to USD 714 million.
The company generated USD 3.489 billion in free cash flow and maintained a 48.4 percent non-GAAP operating margin.
Amgen announced positive Phase 3 results for dazodalibep in Sjogren's disease, adding a major clinical catalyst to its pipeline.
The stock is trading in the upper half of its 52-week range, indicating sustained investor interest despite neutral analyst ratings.
Risk Factors
Cantor Fitzgerald cited a need to reset expectations for Lp(a) products following recent HORIZON results.
The current stock price of USD 404.83 trades above the average analyst target of USD 385.25, suggesting potential downside pressure if consensus holds.
Scotiabank analyst Louise Chen raised her price target for Amgen Inc. from USD 450.00 to USD 500.00, maintaining an outperform rating. This significant upward revision of 11.11 percent reflects the company's strong recent financial performance and positive pipeline developments, positioning the stock as a key focus for institutional investors despite current trading levels below its 52-week high.
Amgen reported robust second-quarter results that exceeded market expectations, with revenue reaching USD 10.05 billion, a 9.50 percent year-over-year increase. The company beat consensus estimates by USD 620 million, and adjusted earnings per share climbed to USD 6.29 against a forecast of USD 5.62. Additionally, the firm declared a quarterly dividend of USD 2.52 per share, offering a yield of approximately 2.50 percent to shareholders.
Beyond financial metrics, Amgen achieved a major clinical milestone with its Phase 3 OASIZ 301 study for dazodalibep meeting its primary endpoint in patients with systemic Sjogren's disease. The study demonstrated statistically significant and clinically meaningful improvements in disease activity as early as Week 4, with sustained benefits observed at Week 48. Further data from the related OASIZ 303 study is expected to be completed by the fourth quarter of 2026.
Trading on the Nasdaq, Amgen shares were valued around USD 403.04 as of late October 2026, trading within a 52-week range of USD 288.00 to USD 447.03. With a market capitalization of approximately USD 217.5 billion, the biopharmaceutical giant remains a component of both the Dow Jones Industrial Average and the Nasdaq-100 index, underscoring its established position in the healthcare sector.
📈 Scotiabank raised Amgen price target to USD 500 with outperform rating.
💰 Q2 revenue hit USD 10.05 billion, beating estimates by USD 620 million.
📊 Adjusted EPS reached USD 6.29 while quarterly dividend declared at USD 2.52.
🧬 Phase 3 OASIZ 301 study met primary endpoint in Sjogren's disease patients.
📅 Related Phase 3 OASIZ 303 study expected to complete in Q4 2026.
📈 Scotiabank analyst Louise Chen raised the price target for Amgen stock from USD 450.00 to USD 500.00 while maintaining an outperform rating.
💰 Amgen reported second-quarter revenue of USD 10.05 billion, surpassing consensus estimates by USD 620 million and growing 9.50% year over year.
📊 Adjusted earnings per share reached USD 6.29, beating the USD 5.62 consensus estimate, while a quarterly dividend of USD 2.52 was declared.
🧬 The Phase 3 OASIZ 301 study for dazodalibep met its primary endpoint in Sjogren's disease patients with statistically significant improvement at Week 48.
📅 The related Phase 3 OASIZ 303 study is expected to complete in the fourth quarter of 2026, providing a defined clinical milestone.
🏢 Amgen maintains a market capitalization of USD 217.5 billion and trades within a 52-week range of USD 288.00 to USD 447.03 on the Nasdaq.
📉 The stock was trading at approximately USD 403.04 in late October 2026, below its previous 52-week high but supported by strong analyst sentiment.
Bullish Signals
Scotiabank raised price target to USD 500.00, outperform rating maintained.
Q2 revenue hit USD 10.05B, beating consensus by USD 620M.
Adjusted EPS of USD 6.29 significantly beat the USD 5.62 estimate.
Phase 3 OASIZ 301 study met primary endpoint in Sjogren's disease.
Declared quarterly dividend of USD 2.52 per share, yielding 2.50%.
Bullish Signals
Scotiabank raised its price target for Amgen from USD 450.00 to USD 500.00, an increase of 11.11 percent, while maintaining an outperform rating.
Second-quarter revenue reached USD 10.05 billion, exceeding analyst consensus by USD 620 million and growing 9.50% year over year.
Adjusted earnings per share of USD 6.29 significantly beat the USD 5.62 consensus estimate, demonstrating strong profitability.
The Phase 3 OASIZ 301 study for dazodalibep met its primary endpoint in Sjogren's disease patients with clinically meaningful improvement observed as early as Week 4.
Amgen declared a quarterly dividend of USD 2.52 per share, providing a 2.50% yield to investors.
The company is a major component of the Dow Jones Industrial Average and Nasdaq-100 with a market capitalization of USD 217.5 billion.
Amgen Inc. reported second-quarter 2026 revenue of USD 10.05 billion, surpassing the consensus estimate of USD 9.43 billion by USD 620 million. This represents a 9.5 percent year-over-year increase in quarterly revenue, driven by strong commercial growth from its core portfolio. Despite this positive financial beat, Amgen's stock price fell 1.04 percent to close at USD 403.04 on October 2, 2026, as investors weighed the earnings result against the company's elevated valuation and ongoing demands for pipeline execution.
Management provided fiscal 2026 EPS guidance ranging from USD 22.30 to USD 23.50 and projected a non-GAAP operating margin between 45 percent and 46 percent for the year. The company highlighted six key growth drivers that expanded 26 percent year over year, which accounted for 70 percent of second-quarter product sales. This strategic focus underscores Amgen's commitment to balancing continued research investment with strict profitability discipline as it navigates its current market position.
Beyond financial metrics, Amgen presented positive topline phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease and shared recent progress on IMDELLTRA. The company also detailed its portfolio and pipeline updates at various healthcare conferences held in September 2026. These developments reinforce the investment case by demonstrating tangible advancements in late-stage development alongside robust commercial performance.
Amgen's market capitalization stood at USD 217.5 billion as of October 2, 2026, with shares trading 9.8 percent below its 52-week high of USD 447.03. The session volume reached 3,502,867 shares, reflecting active investor engagement despite the price decline. The central narrative for investors remains the interplay between strong numerical execution and the need to deliver on future growth expectations to justify current valuations.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)